|
000
| 02776nam 2200481zi 4500 |
|---|
| 001 | 9.923285 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20230907131433 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 230529e20230609onc ob f000 0 eng d |
|---|
| 020 | |a9780660489308 |q(statement) |
|---|
| 020 | |a9780660489315 |q(summary) |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP5-158/1-2023E-PDF |
|---|
| 086 | 1 |aHP5-158/2-2023E-PDF |
|---|
| 245 | 00|aInterim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series. |
|---|
| 246 | 17|aGuidance on bivalent Omicron-containing COVID-19 vaccines for primary series |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c2023. |
|---|
| 264 | 4|c©2023 |
|---|
| 300 | |a1 online resource (19 pages) + |esummary (4 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Directives provisoires sur l'utilisation de vaccins bivalents contre la COVID-19 contenant Omicron dans le cadre d'une série primaire. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |aOn cover: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). |
|---|
| 500 | |a"Pub.: 230092"--Verso of cover. |
|---|
| 500 | |a"Pub.: 230094"--Verso of cover (summary). |
|---|
| 504 | |aIncludes bibliographical references (pages 15-19). |
|---|
| 650 | 0|aCOVID-19 vaccines|zCanada. |
|---|
| 650 | 0|aCOVID-19 (Disease)|xVaccination|zCanada. |
|---|
| 650 | 0|aCOVID-19 vaccines|xGovernment policy|zCanada. |
|---|
| 650 | 0|aCOVID-19 (Disease)|xVaccination|xGovernment policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tDirectives provisoires sur l'utilisation de vaccins bivalents contre la COVID-19 contenant Omicron dans le cadre d'une série primaire.|w(CaOODSP)9.923287 |
|---|
| 856 | 40|qPDF|s638 KB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP5-158-1-2023-eng.pdf|z(statement) |
|---|
| 856 | 40|qPDF|s415 KB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP5-158-2-2023-eng.pdf|z(summary) |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-interim-guidance-use-bivalent-omicron-containing-covid-19-vaccines-primary-series.html|z(statement) |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-interim-guidance-use-bivalent-omicron-containing-covid-19-vaccines-primary-series.html|z(summary) |
|---|